Breast Cancer

Circulating Tumor Cells (CTCs)

Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.

Digoxin

Breast Cancer Center, University Hospital Basel

Digoxin Induced Dissolution of CTC Clusters

Effect of Digoxin on Clusters of Circulating Tumor Cells (CTCs) in Breast Cancer Patients

mean CTC cluster size (in patients with a digoxin serum level above 0.7 ng/ml) after treatment will be compared to mean CTC-cluster size before treatment

number of CTC-clusters before and after treatment will be compared

average time to dissolution of CTC clusters

University Hospital, Basel, Switzerland

Erosive Gastritis

PDC339

Placebo

Department of Internal Medicine, National Taiwan University Hospital

A Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis

A Randomized, Double-Blind, Placebo-Controlled, Parallel Comparative Phase II Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis

glycoside/cancer du sein

Digoxin Induced Dissolution of CTC Clusters

A Clinical Trial to Evaluate the Efficacy and Safety of PDC-339 for the Treatment of Acute Erosive Gastritis

La base de données d'herbes médicinales la plus complète soutenue par la science